CLIAwaived, Inc. has been named the first authorized approved distributor for Wondfo USA’s innovative WELLlife™ COVID-19/Influenza A&B Point-of-Care (POC) and Home (Over-the-Counter) Tests. This collaboration marks a significant milestone in the fight against respiratory infections, providing healthcare professionals and consumers with access to reliable, rapid testing solutions for COVID-19 and influenza A&B.
CARLSBAD, CA / ACCESSWIRE / May 14, 2024 / CLIAwaived, Inc., a leading distributor of point-of-care testing products, has been named the first authorized approved distributor for Wondfo USA’s innovative WELLlife™ COVID-19/Influenza A&B Point-of-Care (POC) and Home (Over-the-Counter) Tests. This collaboration marks a significant milestone in the fight against respiratory infections, providing healthcare professionals and consumers with access to reliable, rapid testing solutions for COVID-19 and influenza A&B.
Wondfo USA, a global leader in rapid diagnostic testing, has developed the WELLlife™ COVID-19/Influenza A&B tests to meet the growing demand for accurate and accessible testing options. These tests offer simultaneous detection of SARS-CoV-2 (COVID-19) and influenza A&B viruses, allowing for comprehensive respiratory virus screening in both clinical and home settings.
As the first authorized approved distributor for these groundbreaking tests, CLIAwaived, Inc. will play a key role in making them available to healthcare providers, pharmacies, and consumers across the United States. Leveraging its extensive distribution network and commitment to quality, CLIAwaived, Inc. aims to ensure widespread access to these vital testing tools, empowering individuals and communities to take proactive steps in managing respiratory infections.
“We are thrilled to partner with Wondfo USA as the first authorized approved distributor for the WELLlife™ COVID-19/Influenza A&B tests,” said Tim Drapeau, CEO of CLIAwaived, Inc. “This collaboration aligns with our mission to provide healthcare professionals and consumers with innovative, reliable testing solutions. By offering simultaneous detection of COVID-19 and influenza A&B viruses, these tests have the potential to streamline diagnostic workflows and improve patient outcomes.”
The WELLlife™ COVID-19/Influenza A&B tests utilize lateral flow technology to deliver rapid results in as little as 15 minutes, enabling timely decision-making and appropriate patient management. With their easy-to-use design and high sensitivity and specificity, these tests offer a valuable tool for screening individuals with respiratory symptoms and identifying cases of COVID-19 and influenza A&B.
“We are excited to partner with CLIAwaived, Inc. to bring our WELLlife™ COVID-19/Influenza A&B tests to healthcare professionals and consumers across the United States,” said Elaine Zhang, Vice President of Regulatory and Upstream Marketing of Wondfo USA. “By combining our expertise in rapid diagnostic testing with CLIAwaived’s extensive distribution network, we aim to make comprehensive respiratory virus testing more accessible and convenient than ever before.”
The WELLlife™ COVID-19/Influenza A&B POC and Home (OTC) Tests are currently available for purchase through CLIAwaived, Inc. To learn more about these tests or place an order, visit CLIAwaived, Inc.’s website.
About Wondfo USA Co., Ltd.
Wondfo USA Co., Ltd. is a high-tech enterprise focusing on the research, development, production, sales, and service of point-of-care testing (POCT) products. Wondfo USA distributes rapid products in four major categories including Toxicology Testing, Infectious Disease, Women’s Reproductive Health, and Veterinary Diagnostics. Wondfo’s diagnostic products are sold in more than 140 countries and regions, and are widely used in various settings, including clinical testing, critical care medicine, primary care, epidemic monitoring, disaster rescue, on-site law enforcement, and family health management. With a strong commitment to innovation and quality, Wondfo aims to make significant contributions to the global healthcare industry. To learn more visit wondfousa.com.
About CLIAwaived.com:
CLIAwaived Inc. (www.cliawaived.com) is a leading marketing and distributor of point-of-care testing solutions, committed to delivering innovative and reliable diagnostic products to healthcare professionals. With a focus on quality and regulatory compliance, CLIAwaived.com empowers healthcare providers and pharmacies performing waived tests with tools that enhance patient care and streamline diagnostic processes.
SOURCE: CLIAwaived, Inc.
View the original press release on accesswire.com
HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…
This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…
Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…
SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…